Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5394392 | 0.80 | CA1 (0.43) | KCNN4MAPK1ALDH1A1TAAR1KMT2A | |
| SCHEMBL462758 | 0.79 | KCNN4 (0.50) | KCNN4MAPK1CES1ALDH1A1TAAR1 | |
| SCHEMBL8524041 | 0.78 | KCNN4 (0.55) | KCNN4MAPK1ALDH1A1TAAR1ALOX15 | |
| SCHEMBL487231 | 0.78 | MAPK1 (0.48) | KCNN4MAPK1CES1ALDH1A1TAAR1 | |
| SCHEMBL2700899 | 0.77 | MAPK1 (0.48) | KCNN4MAPK1CES1ALDH1A1TAAR1 | |
| Hydrochloric Acid SCHEMBL7899276 | 0.77 | KCNN4 (0.48) | KCNN4MAPK1CES1ALDH1A1TAAR1 | |
| SCHEMBL3478682 | 0.77 | MAPK1 (0.48) | KCNN4MAPK1CES1ALDH1A1TAAR1 | |
| SCHEMBL10622807 | 0.76 | KCNN4 (0.52) | KCNN4MAPK1ALDH1A1TAAR1ALOX15 | |
| SCHEMBL9545629 | 0.75 | KCNN4 (0.46) | KCNN4MAPK1CES1ALDH1A1TAAR1 | |
| SCHEMBL6270358 | 0.74 | MAPK1 (0.44) | KCNN4MAPK1CES1ALDH1A1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683334-B2 | Aqueously soluble and chemically stable glucagon peptides | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3206710-B1 | INCRETIN-INSULIN CONJUGATES | UNIV INDIANA RES & TECH CORP (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20190218268-A1 | AQUEOUSLY SOLUBLE & CHEMICALLY STABLE GLUCAGON PEPTIDES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2019-07-18 | — | — | US | disclosed |
| EP-3463415-A1 | AQUEOUSLY SOLUBLE & CHEMICALLY STABLE GLUCAGON PEPTIDES | Indiana University Research & Technology Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10232020-B2 | Incretin-insulin conjugates | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2017210241-A1 | AQUEOUSLY SOLUBLE & CHEMICALLY STABLE GLUCAGON PEPTIDES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-12-07 | — | — | WO | disclosed |
| EP-2952202-B1 | GIP-BASED MIXED AGONISTS FOR TREATMENT OF METABOLIC DISORDERS AND OBESITY | UNIV INDIANA RES & TECH CORP (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9790263-B2 | GIP receptor-active glucagon compounds | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170281788-A1 | INCRETIN-INSULIN CONJUGATES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2017-10-05 | — | — | US | disclosed |
| EP-3206710-A1 | INCRETIN-INSULIN CONJUGATES | Indiana University Research & Technology Corporation (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-0941122-B1 | COMPOSITIONS FOR POLYNUCLEOTIDE DELIVERY | CHIRON CORP (US) | 2003-10-29 | — | — | EP | disclosed |
| US-6468986-B1 | COMPOSITION COMPRISING POLYNUCLEOTIDE AND POLYCATIONIC AGENT WHICH EXHIBITS NET POSITIVE ELECTRICAL CHARGE AT PHYSIOLOGICAL PH, AND IS CAPABLE OF MEDIATING ENTRY OF POLYNUCLEOTIDES INTO CELL | CHIRON CORPORATION | 2002-10-22 | — | — | US | disclosed |
| US-6251433-B1 | Polycationic polymers | CHIRON CORPORATION | 2001-06-26 | — | — | US | disclosed |
| EP-1104304-A1 | MULTIVALENT AVB3 AND METASTASIS-ASSOCIATED RECEPTOR LIGANDS | G.D. SEARLE & CO. (US) | 2001-06-06 | — | — | EP | disclosed |
| EP-1070085-A1 | DUAL A v?b 3? AND METASTASIS-ASSOCIATED RECEPTOR LIGANDS | G.D. SEARLE & CO. (US) | 2001-01-24 | — | — | EP | disclosed |
| WO-2000009143-A1 | MULTIVALENT AVB3 AND METASTASIS-ASSOCIATED RECEPTOR LIGANDS | G.D. SEARLE & CO. (US) | 2000-02-24 | — | — | WO | disclosed |
| WO-1999051638-A1 | DUAL Avb3 AND METASTASIS-ASSOCIATED RECEPTOR LIGANDS | G.D. SEARLE & CO. (US) | 1999-10-14 | — | — | WO | disclosed |
| EP-0941122-A2 | COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE DELIVERY | CHIRON CORPORATION (US) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998006437-A2 | COMPOSITIONS AND METHODS FOR POLYNUCLEOTIDE DELIVERY | CHIRON CORPORATION (US) | 1998-02-19 | — | — | WO | disclosed |
| CN-1051553-A | ACAT INHIBITORS | WARNER LAMBERT CO (US) | 1991-05-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218268-A1 | AQUEOUSLY SOLUBLE & CHEMICALLY STABLE GLUCAGON PEPTIDES | IAPP, GLP1R, GCG | KCNN4 3553/4885MAPK1 1304/4885CES1 2831/4885 |
| US-10683334-B2 | Aqueously soluble and chemically stable glucagon peptides | IAPP, GLP1R, GCG | KCNN4 3751/4885MAPK1 959/4885CES1 2395/4885 |
| US-20170281788-A1 | INCRETIN-INSULIN CONJUGATES | GPR119, GLP1R, GIPR | KCNN4 3428/4885MAPK1 2873/4885CES1 410/4885 |
| US-10232020-B2 | Incretin-insulin conjugates | GPR119, GLP1R, GIPR | KCNN4 3428/4885MAPK1 2873/4885CES1 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.